Gilead's Truvada may protect against HIV but compliance and cost may erode health benefit
This article was originally published in Scrip
Executive Summary
Gilead Sciences' Truvada, a fixed-dose combination of two antiretrovirals used for the treatment of HIV, may offer protection against contracting the virus.